1. Home
  2. VCIG vs GANX Comparison

VCIG vs GANX Comparison

Compare VCIG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

HOLD

Current Price

$0.67

Market Cap

4.0M

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.55

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VCIG
GANX
Founded
2013
2017
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0M
159.2M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
VCIG
GANX
Price
$0.67
$2.55
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
1.5M
2.1M
Earning Date
01-21-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.98
N/A
Revenue
$32,903,041.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.62
N/A
Revenue Growth
24.77
N/A
52 Week Low
$0.51
$1.41
52 Week High
$1,290.00
$4.34

Technical Indicators

Market Signals
Indicator
VCIG
GANX
Relative Strength Index (RSI) 39.30 39.79
Support Level $0.51 $2.98
Resistance Level $0.68 $3.29
Average True Range (ATR) 0.07 0.49
MACD 0.05 -0.11
Stochastic Oscillator 81.77 19.44

Price Performance

Historical Comparison
VCIG
GANX

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: